Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist.

Ward JA, Furr BJ, Valcaccia B, Curry B, Bardin CW, Gunsalus GL, Morris ID

Journal of andrology1 Nov 1989Cited by 17 (Europe PMC)

PMID2533593DOI10.1002/j.1939-4640.1989.tb00144.xPepBankPUB-02533593

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin caused sustained decreases in testis weight, apparent within two weeks.
In plain wordsIn rats, goserelin reduced testis weight within two weeks.
Peptide
Goserelin
Outcome
DecreaseTestis weight
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Administration of Zoladex resulted in sustained decreases in weight of the testis, epididymis, seminal vesicles and prostate gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The decreases were apparent within 2 wk of initiating treatment.
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359301
02AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin caused sustained decreases in epididymis weight, apparent within two weeks.
In plain wordsIn rats, goserelin reduced epididymis weight within two weeks.
Peptide
Goserelin
Outcome
DecreaseEpididymis weight
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Administration of Zoladex resulted in sustained decreases in weight of the testis, epididymis, seminal vesicles and prostate gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The decreases were apparent within 2 wk of initiating treatment.
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359302
03AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin caused sustained decreases in seminal vesicle weight, apparent within two weeks.
In plain wordsIn rats, goserelin reduced seminal vesicle weight within two weeks.
Peptide
Goserelin
Outcome
DecreaseSeminal vesicle weight
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Administration of Zoladex resulted in sustained decreases in weight of the testis, epididymis, seminal vesicles and prostate gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The decreases were apparent within 2 wk of initiating treatment.
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359303
04AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin caused sustained decreases in prostate weight, apparent within two weeks.
In plain wordsIn rats, goserelin reduced prostate weight within two weeks.
Peptide
Goserelin
Outcome
DecreaseProstate weight
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Administration of Zoladex resulted in sustained decreases in weight of the testis, epididymis, seminal vesicles and prostate gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The decreases were apparent within 2 wk of initiating treatment.
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359304
05AnimalAnimal study (in vivo)Safety outcome
In male rats, goserelin produced patchy seminiferous tubule degeneration that did not progress beyond the degree seen after one month.
In plain wordsIn rats, goserelin caused patchy testicular tubule damage that did not progress beyond the degree seen after one month.
Peptide
Goserelin
Outcome
IncreaseSeminiferous tubule degeneration
Study
ratn: not reported in source
Male rats
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Patchy degeneration of the seminiferous tubules and atrophy of the Leydig cells were observed, but did not progress beyond the degree observed after 1 month of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359305
06AnimalAnimal study (in vivo)Safety outcome
In male rats, goserelin produced Leydig cell atrophy that did not progress beyond the degree seen after one month.
In plain wordsIn rats, goserelin caused Leydig cell shrinkage that did not progress beyond the degree seen after one month.
Peptide
Goserelin
Outcome
IncreaseLeydig cell atrophy
Study
ratn: not reported in source
Male rats
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Patchy degeneration of the seminiferous tubules and atrophy of the Leydig cells were observed, but did not progress beyond the degree observed after 1 month of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359306
07AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin markedly depressed serum testosterone after two weeks.
In plain wordsIn rats, goserelin markedly reduced blood testosterone after two weeks.
Peptide
Goserelin
Outcome
DecreaseSerum testosterone
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum and testis testosterone were markedly depressed after 2 wk of treatment, as was testis [125I]hCG binding.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359307
08AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin markedly depressed testis testosterone after two weeks.
In plain wordsIn rats, goserelin markedly reduced testis testosterone after two weeks.
Peptide
Goserelin
Outcome
DecreaseTestis testosterone
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum and testis testosterone were markedly depressed after 2 wk of treatment, as was testis [125I]hCG binding.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359308
09AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin depressed testis hCG binding after two weeks.
In plain wordsIn rats, goserelin reduced testis hCG binding after two weeks.
Peptide
Goserelin
Outcome
DecreaseTestis hCG binding
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum and testis testosterone were markedly depressed after 2 wk of treatment, as was testis [125I]hCG binding.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359309
10AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin reduced serum gonadotropins.
In plain wordsIn rats, goserelin reduced blood gonadotropins.
Peptide
Goserelin
Outcome
DecreaseSerum gonadotropins
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum gonadotropins were also reduced by treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359310
11AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin elevated serum androgen binding protein.
In plain wordsIn rats, goserelin increased blood androgen binding protein.
Peptide
Goserelin
Outcome
IncreaseSerum androgen binding protein
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum androgen binding protein (ABP) was elevated, testis ABP content remained unchanged, and epididymal ABP content was reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359311
12AnimalAnimal study (in vivo)Activity measurement
In male rats, testis androgen binding protein content remained unchanged during goserelin treatment.
In plain wordsIn rats, testis androgen binding protein remained unchanged during goserelin treatment.
Peptide
Goserelin
Outcome
No significant changeTestis androgen binding protein
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum androgen binding protein (ABP) was elevated, testis ABP content remained unchanged, and epididymal ABP content was reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359312
13AnimalAnimal study (in vivo)Activity measurement
In male rats, goserelin reduced epididymal androgen binding protein content.
In plain wordsIn rats, goserelin reduced epididymal androgen binding protein.
Peptide
Goserelin
Outcome
DecreaseEpididymal androgen binding protein
Study
ratn: not reported in source
Male rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg/depot every 28 days · subcutaneous · 2-24 wkAs given in this study (rat).
Source sentences
Summary
Serum androgen binding protein (ABP) was elevated, testis ABP content remained unchanged, and epididymal ABP content was reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis funct…
Report a problemFND-0253359313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.